{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:ema:opdivo:8 retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Aema%3Aopdivo%3A8",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.034268,
    "timestamp_received": "2026-09-25T06:02:17.880533+00:00Z",
    "timestamp_returned": "2026-09-25T06:02:17.914801+00:00Z",
    "trace_id": "c7766bb7-e1c9-4b46-9a26-bb4c0c6b9f93"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-08-02"
  },
  "data": [
    {
      "id": "ind:ema:opdivo:8",
      "type": "Indication",
      "description": "OPDIVO in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by OPDIVO as monotherapy as adjuvant treatment, is indicated for the treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumors have PD-L1 expression >= 1%.",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2025-09-04:1",
          "type": "Contribution",
          "description": "On 2025-06-02, the EMA published an EPAR - Assessment report - Variation for Opdivo (nivolumab) for that added an extension indication to nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment, followed by nivolumab as monotherapy as adjuvant treatment, of patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors have PD-L1 expression >= 1%.",
          "date": "2025-09-04",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        },
        {
          "id": "ctrb:ema:2025-05-15:0",
          "type": "Contribution",
          "description": "Indication received approval from the European Commission.",
          "date": "2025-05-15",
          "contributor": {
            "id": "agent:org:ema",
            "type": "Agent",
            "agentType": "organization",
            "name": "European Medicines Agency",
            "description": "Regulatory agency that approves medicines for use in the European Union."
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:ema:opdivo",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Opdivo (nivolumab) [product information]. EMA.",
          "title": null,
          "aliases": [],
          "description": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised June 2025. Accessed September 5, 2025.",
          "urls": [
            "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf",
            "https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:ema",
                "type": "Agent",
                "agentType": "organization",
                "name": "European Medicines Agency",
                "description": "Regulatory agency that approves medicines for use in the European Union."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Bristol-Myers Squibb Pharma EEIG.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Opdivo",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "nivolumab",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2015-07-16",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2025-06-02",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "extensions": [
        {
          "name": "status",
          "value": "Approved",
          "description": "Current approval status."
        }
      ]
    }
  ]
}